Literature DB >> 12646755

Effects of mitoxantrone on multiple sclerosis patients' lymphocyte subpopulations and production of immunoglobulin, TNF-alpha and IL-10.

Joystone Gbadamosi1, Carsten Buhmann, Wiebke Tessmer, Andrea Moench, Friedrich Haag, Christoph Heesen.   

Abstract

We designed this longitudinal study to clarify the short- and long-term effects of mitoxantrone on the immune system in a subgroup of multiple sclerosis patients treated at our centre. After 14 days we found a highly significant sustained reduction of leucocytes, primarily affecting neutrophils and most lymphocyte subsets except for naive and activated T lymphocytes. The CD4/CD8 ratio and serum immmunoglobulin levels were not affected. Furthermore, whole blood-stimulated mononuclear cell IL-10 production showed a significant lower level 2 weeks treatment, whereas basal IL-10 as well as stimulated and basal TNF-alpha secretion showed no significant changes. Longitudinal data disclosed a persistent decrease of B lymphocytes, while secretion of immunoglobulins, IL-10, and TNF-alpha was not altered in the follow-up. In conclusion, we confirmed a selective short-term effect of mitoxantrone therapy on most lymphocyte subpopulations, but not on immunoglobulines or the pro- and anti-inflammatory cytokines TNF-alpha and IL-10, which do not serve as possible response markers. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12646755     DOI: 10.1159/000069082

Source DB:  PubMed          Journal:  Eur Neurol        ISSN: 0014-3022            Impact factor:   1.710


  16 in total

Review 1.  Immunosuppressive agents in multiple sclerosis.

Authors:  Oliver Neuhaus; Bernd C Kieseier; Hans-Peter Hartung
Journal:  Neurotherapeutics       Date:  2007-10       Impact factor: 7.620

Review 2.  Aggressive multiple sclerosis: proposed definition and treatment algorithm.

Authors:  Carolina A Rush; Heather J MacLean; Mark S Freedman
Journal:  Nat Rev Neurol       Date:  2015-06-02       Impact factor: 42.937

Review 3.  Seeking balance: Potentiation and inhibition of multiple sclerosis autoimmune responses by IL-6 and IL-10.

Authors:  Sara J Ireland; Nancy L Monson; Laurie S Davis
Journal:  Cytokine       Date:  2015-03-17       Impact factor: 3.861

4.  Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients.

Authors:  A Chan; F X Weilbach; K V Toyka; R Gold
Journal:  Clin Exp Immunol       Date:  2005-01       Impact factor: 4.330

Review 5.  [Mitoxanthrone in the therapy of multiple sclerosis].

Authors:  B C Kieseier; R Gold; H-P Hartung
Journal:  Nervenarzt       Date:  2003-10       Impact factor: 1.214

6.  Treatment of multiple sclerosis with methylprednisolone and mitoxantrone modulates the expression of CXC chemokine receptors in PBMC.

Authors:  Bartosz Bielecki; Andzelika Mazurek; Paweł Wolinski; Andrzej Glabinski
Journal:  J Clin Immunol       Date:  2007-10-25       Impact factor: 8.317

Review 7.  B cells: no longer the nondominant arm of multiple sclerosis.

Authors:  Eric C Klawiter; Anne H Cross
Journal:  Curr Neurol Neurosci Rep       Date:  2007-05       Impact factor: 6.030

8.  Mitoxantrone induces natural killer cell maturation in patients with secondary progressive multiple sclerosis.

Authors:  Coralie Chanvillard; Jason M Millward; Marta Lozano; Isabell Hamann; Friedemann Paul; Frauke Zipp; Jan Dörr; Carmen Infante-Duarte
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

Review 9.  Rituximab in Multiple Sclerosis: Are We Ready for Regulatory Approval?

Authors:  Serena Brancati; Lucia Gozzo; Laura Longo; Daniela Cristina Vitale; Filippo Drago
Journal:  Front Immunol       Date:  2021-07-06       Impact factor: 7.561

Review 10.  The Role of B Cells in Primary Progressive Multiple Sclerosis.

Authors:  Jameson P Holloman; Robert C Axtell; Nancy L Monson; Gregory F Wu
Journal:  Front Neurol       Date:  2021-06-07       Impact factor: 4.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.